Road Tripping with a Wheelchair

The two-lane highway stretches to an infinite distance. It’s just you, the droning road noise and the horizon. It’s a time to think and ask yourself questions you never had […]

Hogan Family

Raising Awareness and Funding Duchenne Research: Christian Hogan and his 22-year-old son Micah, who has Duchenne, envisioned this event after attending a reggae show in Long Beach several years ago.

Edgewise Therapeutics Announces Positive 12-Month Topline Results From The ARCH Open Label Study Of EDG-5506 In Adults With Becker Muscular Dystrophy (BMD)

The positive results from the 12-month ARCH study support the hypothesis that a reduction in contraction-induced muscle damage in muscular dystrophies, associated with EDG-5506 administration, has the potential to preserve and improve muscle function while preventing disease progression in dystrophinopathies. Observations from ARCH identified key factors, including the optimal dosing strategy of EDG-5506, for the design of a potentially registrational trial. A pivotal cohort, GRAND CANYON, has been added to the CANYON study and is anticipated to begin enrollment in the third quarter of 2023.